Research map: Establishment of epidemiological cutoff values for yeast-phase Talaromyces marneffei against six antifungal agents: a multicenter study in China

Back to the article

Papers in this map

  1. Worldwide emergence of resistance to antifungal drugs challenges human health and food security · Matthew C. Fisher · 2018 · 1591 citations · Cited by this paper
  2. PER-14, a β-lactamase variant with reduced sensitivity to avibactam and relebactam · 2026 · Related
  3. Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease · Andrew J. Ullmann · 2007 · 1347 citations · Cited by this paper
  4. An Achilles' heel for methicillin-resistant Staphylococcus aureus ? Re-evaluating β-lactam susceptibility of MRSA · 2026 · Related
  5. Frequency and Evolution of Azole Resistance in Aspergillus fumigatus Associated with Treatment Failure1 · Susan Julie Howard · 2009 · 758 citations · Cited by this paper
  6. A community-based One Health approach to the pandemic dynamics of Escherichia coli ST131 · 2026 · Related
  7. Cryptococcus neoformans-Cryptococcus gattii Species Complex: an International Study of Wild-Type Susceptibility Endpoint Distributions and Epidemiological Cutoff Values for Fluconazole, Itraconazole, Posaconazole, and Voriconazole · Ana Espinel‐Ingroff · 2012 · 252 citations · Cited by this paper
  8. Development of domain-specific probes of Plasmodium falciparum heat shock protein 70-1 · 2026 · Related
  9. Infection Caused by Penicillium marneffei : Description of First Natural Infection in Man · Arthur F. DiSalvo · 1973 · 202 citations · Cited by this paper
  10. Population pharmacokinetics of ritonavir-boosted atazanavir in subsequent-line treatment in African children with HIV · 2026 · Related
  11. Talaromycosis (Penicilliosis) Due to Talaromyces (Penicillium) marneffei: Insights into the Clinical Trends of a Major Fungal Disease 60 Years After the Discovery of the Pathogen · Cunwei Cao · 2019 · 180 citations · Cited by this paper
  12. Primaquine-derived 5,6-orthoquinone concentrations in urine associated with CYP2D6 genotype-predicted phenotype and blood methemoglobin levels · 2026 · Related
  13. In Vitro Antifungal Activity of Micafungin (FK463) against Dimorphic Fungi: Comparison of Yeast-Like and Mycelial Forms · Toru Nakai · 2003 · 157 citations · Cited by this paper
  14. Selective digestive decontamination and antimicrobial resistance: defining thresholds before global implementation · 2026 · Related
  15. An Overlooked and Underrated Endemic Mycosis—Talaromycosis and the Pathogenic Fungus Talaromyces marneffei · Fang Wang · 2023 · 135 citations · Cited by this paper
  16. Recalculation of inhibitor concentration fold-changes for CMY-219: comments on a recent article about CMY-219 conferring resistance to ceftazidime-avibactam · 2026 · Related
  17. Establishment and Use of Epidemiological Cutoff Values for Molds and Yeasts by Use of the Clinical and Laboratory Standards Institute M57 Standard · Shawn R. Lockhart · 2017 · 81 citations · Cited by this paper
  18. NagX, a periplasmic β- N -acetylglucosaminidase, contributes to NagZ-independent β-lactamase expression in Stenotrophomonas maltophilia · 2026 · Related
  19. Voriconazole as Therapy for Systemic Penicillium marneffei Infections in AIDS Patients · Khuanchai Supparatpinyo · 2007 · 70 citations · Cited by this paper
  20. Anti-RSV drug screening and inhibition of RSV infection by lapatinib through the IL-17 pathway · 2026 · Related
  21. In vitro sensitivity of Penicillium marneffei and Pythium insidiosum to various antifungal agents · Awatar S. Sekhon · 1992 · 54 citations · Cited by this paper
  22. Susceptibility profile of echinocandins, azoles and amphotericin B against yeast phase of Talaromyces marneffei isolated from HIV-infected patients in Guangdong, China · Huali Lei · 2018 · 54 citations · Cited by this paper
  23. In Vitro Activity of Posaconazole against Talaromyces marneffei by Broth Microdilution and Etest Methods and Comparison to Itraconazole, Voriconazole, and Anidulafungin · Susanna K. P. Lau · 2016 · 34 citations · Cited by this paper
  24. In vitro interactions of micafungin with amphotericin B, itraconazole or fluconazole against the pathogenic phase of Penicillium marneffei · Chen Cao · 2008 · 31 citations · Cited by this paper
  25. Calcineurin A Is Essential in the Regulation of Asexual Development, Stress Responses and Pathogenesis in Talaromyces marneffei · Yanqing Zheng · 2020 · 16 citations · Cited by this paper
  26. Study on the mechanisms of action of berberine combined with fluconazole against fluconazole-resistant strains of Talaromyces marneffei · Kaisu Pan · 2022 · 10 citations · Cited by this paper
  27. Fatal Talaromyces marneffei Infection in a Patient with Autoimmune Hepatitis · Sally C. Y. Wong · 2018 · 9 citations · Cited by this paper
  28. Establishment of epidemiological cutoff values for Fonsecaea pedrosoi , the primary etiologic agent of chromoblastomycosis, and eight antifungal medications · Dallas J. Smith · 2025 · 8 citations · Cited by this paper
  29. Comparison of in vitro Susceptibilities of Talaromyces marneffei in Mold and Yeast Forms in Malaysia · Xue Ting Tan · 2023 · 7 citations · Cited by this paper
  30. A 40-year antifungal susceptibility surveillance of Talaromyces marneffei (1984–2024) at a tertiary hospital in Guangxi, China · Xinyu Zhou · 2025 · 6 citations · Cited by this paper
  31. Potential risk of cross-resistance to voriconazole in HIV/AIDS patients with Talaromyces marneffei infection and the mechanisms of the cross-resistance · Yan-Qing Zheng · 2025 · 5 citations · Cited by this paper
  32. Disseminated Talaromyces marneffei infection mimicking tuberculosis in an HIV-negative adult with anti–IFN-γ autoantibodies: a case report · Jiewei Liu · 2025 · 3 citations · Cited by this paper
  33. Clinical Talaromyces marneffei isolates exhibit enhanced stress tolerance and diminished antifungal responsiveness relative to non-clinical strains · Kaisu Pan · 2026 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)